期刊文献+

慢性宫颈炎患者治疗前后机体免疫机制变化的临床分析 被引量:6

慢性宫颈炎患者治疗前后机体免疫机制变化的临床分析
下载PDF
导出
摘要 目的探讨300例慢性宫颈炎患者治疗前后机体免疫机制变化。方法本文对300例慢性宫颈炎患者治疗前后机体的免疫球蛋白水平进行测定,并对治疗前后的变化情况进行对比分析。结果 300例慢性宫颈炎患者接受治疗愈合时间在30~40d,愈合过程脱痂时未出现阴道出血、宫颈炎性结节形成、宫颈粘连、宫颈瘢痕等并发症;其中253例患者治疗后IgA、IgG、IgM较治疗前均呈现逐渐升高的趋势。结论慢性宫颈炎患者在患病期间自身的免疫能力处于相对静止状态,抗病能力低下,治疗后激活了宫颈组织细胞的再生能力,激发了机体的免疫功能,提高了机体的免疫应答反应,分泌并产生免疫球蛋白IgA、IgG、IgM,提高了机体的抗病能力。 Objective To investigate the immune mechanism change before and after treating 300 cases chronic cervicitis patients. Methods 300 cases of chronic cervicitis patients before and after treatment with immune globulin levels were measured, and the change before and after the treatment were analyzed. Results 300 cases of chronic cervicitis treated healing time in 30-40d, there were no healing scab off when vaginal bleeding, inflammatory nodule formation, cervical adhesions, cervical scar complications; among the 253 patients after treatment with IgA, IgG, IgM than before treatment all showed increasing trend. Conclusion Chronic Cervicitis Patients in the period prevalence of immunity is in the state of relative rest, disease-resistant ability is low, treatment after activation of the cervical tissue regeneration, stimulate the body's immune function, improve the body immune response system, secretion and immunoglobulin IgA, IgG, IgM, enhance the body's resistance ability.
出处 《当代医学》 2012年第7期47-47,共1页 Contemporary Medicine
关键词 慢性宫颈炎 机体 免疫机制 Chronic cervicitis Body Immune mechanism
  • 相关文献

参考文献3

二级参考文献5

共引文献255

同被引文献64

  • 1国家中医药管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:29.
  • 2Hickey DK, Patel MV, Fahey JV, et al. Innate and adap- tive immunity at mucosal surfaces of the female reproductive tract stratification and integration of immune protection a- gainst the transmission of sexually transmitted infection. J Reprod Immunol, 2011, 88: 185- 194.
  • 3Wira CR, Fahey JV, Ghosh M, et al. Sex hormone regula- tion of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Re-prod Immunol, 2010, 63: 544- 565.
  • 4Okada H, Okamoto R, Tsuzuki T, et al. Progestins inhibit estradio lindueed vascular endothelial growth factor and stro- mal cell derived factor 1 in human endometrial stromal cells. Fertil Steril, 2011, 96: 786 - 791.
  • 5Winuthayanon W, Hewitt SC, Orvis GD, et al. Uterine epithelial estrogen receptor a is dispensable for proliferation but essential for complete biological and biochemical respon- ses. Proc Natl Acad Sci USA, 2010, 107: 19272- 19277.
  • 6Gortzak- Uzan L, Jimenez W, Nofech - Mozes S, et al. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard? Gynecol Oncol, 2010, 116: 28-32.
  • 7Silva CS, Michelin MA, Etchebehere MR, et al. Local lym- phocytes and nitric oxide synthase in the uterine cervical stro- ma of patients with grade Ⅲ cervical intraepithelial neoplasia. Clinics (SaoPaulo), 2010, 65: 575-581.
  • 8Fukui Am Matsueda S, Kawano K, et al. Identification of B cell epitopes reactive to human papillomavirus type - 16L1 - derived peptides. VirolJ, 2012, 9: 199.
  • 9Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol, 2010, 10: 699 - 711.
  • 10Naz RK. Female genital tract immunity: distinct immuno logical challenges for vaccine development. J Reprod Immu- nol, 2012, 93: 1-8.

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部